Cargando…
Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study
BACKGROUND: Data on the prevalence of perennial versus seasonal allergic asthma in Italy are lacking; moreover, there is limited evidence on the effect of omalizumab on patient-reported outcomes in Italian patients with severe allergic asthma. PROXIMA, an observational, multicenter study, was design...
Autores principales: | Canonica, Giorgio Walter, Rottoli, Paola, Bucca, Caterina, Zappa, Maria Cristina, Michetti, Giovanni, Macciocchi, Bruno, Caruso, Cristiano, Santus, Pierachille, Bartezaghi, Marta, Rigoni, Laura |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214174/ https://www.ncbi.nlm.nih.gov/pubmed/30410639 http://dx.doi.org/10.1186/s40413-018-0214-3 |
Ejemplares similares
-
Prevalence of perennial severe allergic asthma in Italy and effectiveness of omalizumab in its management: PROXIMA – an observational, 2 phase, patient reported outcomes study
por: Canonica, Giorgio Walter, et al.
Publicado: (2015) -
Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study
por: Canonica, Giorgio Walter, et al.
Publicado: (2020) -
Effectiveness of omalizumab in patients with severe allergic asthma with and without chronic rhinosinusitis with nasal polyps: a PROXIMA study post hoc analysis
por: Heffler, Enrico, et al.
Publicado: (2020) -
Plasma Galectin-3 and urine proteomics predict FEV(1) improvement in omalizumab-treated patients with severe allergic asthma: Results from the PROXIMA sub-study()
por: Riccio, Anna Maria, et al.
Publicado: (2020) -
Predictors of reversible airway obstruction with omalizumab in severe asthma: a real-life study
por: Solidoro, Paolo, et al.
Publicado: (2019)